Shenqi Fuzheng Injection Combined with Chemotherapy for Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

Abstract EN

Purpose.

To evaluate the therapeutic effectiveness and safety of shenqi fuzheng injection (SFI) in the associated chemotherapy of breast cancer.

Methods.

1247 subjects were included in this study for meta-analysis with RevMan 5.3.

Results.

The clinical curative effective rate (OR = 2.03, 95% Cl [1.44, 2.86], P < 0.0001 ), grades of KPS (OR = 4.11, 95% Cl [2.74, 6.16], P < 0.00001 ), CD3+ cells (MD = 7.05, 95% Cl [0.45, 13.64], P = 0.04 ) and CD4+ cells (MD = 8.60, 95% Cl [2.67, 14.54], P = 0.004 ) and CD4/CD8+ cells (MD = 0.35, 95% Cl [0.14, 0.56], P = 0.001 ), WBC (OR = 0.30, 95% Cl [0.20, 0.46], P ≤ 0.0001 ), PLT (OR = 0.36, 95% Cl [0.20, 0.67], P = 0.001 ), gastrointestinal reaction (OR = 0.21, 95% Cl [0.14, 0.32], P < 0.00001 ), and ECG (OR = 0.26, 95% Cl [0.13, 0.51], P < 0.0001 ) in the experimental group were superior to the control group.

While there were no differences between two groups in CD8+ (MD = 0.21, 95% Cl [−2.81, 3.23], P = 0.89 ), NK+ (MD = 1.06, 95% Cl [−9.40, 11.53], P = 0.84 ), RBC (OR = 0.49, 95% Cl [0.14, 1.74], P = 0.27 ), liver function (OR = 0.59, 95% Cl [0.28, 1.24], P = 0.16 ), renal function (OR = 0.56, 95% Cl [0.13, 2.45], P = 0.44 ), and bone marrow suppression (OR = 0.50, 95% Cl [0.25, 1.01], P = 0.05 ).

Conclusion.

SFI combined with chemotherapy, to some extent, can improve the effectiveness and the security in the treatment of breast cancer; the mechanism may be related to the elevated immunity.